Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Outlook Therapeutics (OTLK) Interest Expenses (2016 - 2020)

Outlook Therapeutics has reported Interest Expenses over the past 6 years, most recently at $443624.0 for Q2 2020.

  • Quarterly Interest Expenses fell 58.99% to $443624.0 in Q2 2020 from the year-ago period, while the trailing twelve-month figure was $443624.0 through Dec 2024, changed N/A year-over-year, with the annual reading at $3.2 million for FY2024, 24.72% up from the prior year.
  • Interest Expenses was $443624.0 for Q2 2020 at Outlook Therapeutics, down from $696151.0 in the prior quarter.
  • Over five years, Interest Expenses peaked at $2.1 million in Q3 2017 and troughed at -$788893.0 in Q3 2018.
  • The 5-year median for Interest Expenses is $707017.0 (2017), against an average of $793335.1.
  • Year-over-year, Interest Expenses skyrocketed 482.94% in 2017 and then tumbled 136.74% in 2018.
  • A 5-year view of Interest Expenses shows it stood at $489145.0 in 2016, then surged by 46.76% to $717883.0 in 2017, then soared by 56.13% to $1.1 million in 2018, then tumbled by 46.68% to $597665.0 in 2019, then decreased by 25.77% to $443624.0 in 2020.
  • Per Business Quant, the three most recent readings for OTLK's Interest Expenses are $443624.0 (Q2 2020), $696151.0 (Q1 2020), and $597665.0 (Q4 2019).